Literature DB >> 30801692

Interferon signature in patients with STAT1 gain-of-function mutation is epigenetically determined.

Epp Kaleviste1, Mario Saare1, Timothy Ronan Leahy2, Vincent Bondet3, Darragh Duffy3, Trine H Mogensen4,5,6, Sofie E Jørgensen5, Helke Nurm7, Winnie Ip8, E Graham Davies8, Sascha Sauer9,10, Ann-Christine Syvänen11, Lili Milani12, Pärt Peterson1, Kai Kisand1.   

Abstract

STAT1 gain-of-function (GOF) variants lead to defective Th17 cell development and chronic mucocutaneous candidiasis (CMC), but frequently also to autoimmunity. Stimulation of cells with STAT1 inducing cytokines like interferons (IFN) result in hyperphosphorylation and delayed dephosphorylation of GOF STAT1. However, the mechanism how the delayed dephosphorylation exactly causes the increased expression of STAT1-dependent genes, and how the intracellular signal transduction from cytokine receptors is affected, remains unknown. In this study we show that the circulating levels of IFN-α were not persistently elevated in STAT1 GOF patients. Nevertheless, the expression of interferon signature genes was evident even in the patient with low or undetectable serum IFN-α levels. Chromatin immunoprecipitation (ChIP) experiments revealed that the active chromatin mark trimethylation of lysine 4 of histone 3 (H3K4me3), was significantly enriched in areas associated with interferon-stimulated genes in STAT1 GOF cells in comparison to cells from healthy donors. This suggests that the chromatin binding of GOF STAT1 variant promotes epigenetic changes compatible with higher gene expression and elevated reactivity to type I interferons, and possibly predisposes for interferon-related autoimmunity. The results also suggest that epigenetic rewiring may be responsible for treatment failure of Janus kinase 1/2 (JAK1/2) inhibitors in certain patients.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  STAT1 gain-of-function mutation; autoimmunity; chronic mucocutaneous candidiasis; epigenetics; type I interferon

Mesh:

Substances:

Year:  2019        PMID: 30801692     DOI: 10.1002/eji.201847955

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib.

Authors:  Tariq Al Shehri; Kimberly Gilmour; Florian Gothe; Sam Loughlin; Shahnaz Bibi; Andrew D Rowan; Angela Grainger; Thivytra Mohanadas; Andrew J Cant; Mary A Slatter; Sophie Hambleton; Desa Lilic; Timothy R Leahy
Journal:  J Clin Immunol       Date:  2019-09-11       Impact factor: 8.317

Review 2.  Bivalent Regulation and Related Mechanisms of H3K4/27/9me3 in Stem Cells.

Authors:  Han Sun; Yin Wang; Ying Wang; Feng Ji; An Wang; Ming Yang; Xu He; Lisha Li
Journal:  Stem Cell Rev Rep       Date:  2021-08-21       Impact factor: 5.739

3.  JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia.

Authors:  Jacob M Rosenberg; Joshua M Peters; Travis Hughes; Caleb A Lareau; Leif S Ludwig; Lucas R Massoth; Christina Austin-Tse; Heidi L Rehm; Bryan Bryson; Yi-Bin Chen; Aviv Regev; Alex K Shalek; Sarah M Fortune; David B Sykes
Journal:  Med (N Y)       Date:  2022-01-14

Review 4.  Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.

Authors:  Satoshi Okada; Takaki Asano; Kunihiko Moriya; Stephanie Boisson-Dupuis; Masao Kobayashi; Jean-Laurent Casanova; Anne Puel
Journal:  J Clin Immunol       Date:  2020-08-27       Impact factor: 8.317

5.  Genetic and immunologic findings in children with recurrent aphthous stomatitis with systemic inflammation.

Authors:  Martina Girardelli; Erica Valencic; Valentina Moressa; Roberta Margagliotta; Alessandra Tesser; Serena Pastore; Ottavia Spadola; Emmanouil Athanasakis; Giovanni Maria Severini; Andrea Taddio; Alberto Tommasini
Journal:  Pediatr Rheumatol Online J       Date:  2021-05-10       Impact factor: 3.054

6.  STAT1 gain-of-function heterozygous cell models reveal diverse interferon-signature gene transcriptional responses.

Authors:  Ori Scott; Kyle Lindsay; Steven Erwood; Antonio Mollica; Chaim M Roifman; Ronald D Cohn; Evgueni A Ivakine
Journal:  NPJ Genom Med       Date:  2021-05-14       Impact factor: 8.617

7.  Live Cell Imaging Demonstrates Multiple Routes Toward a STAT1 Gain-of-Function Phenotype.

Authors:  Simone Giovannozzi; Veerle Lemmens; Jelle Hendrix; Rik Gijsbers; Rik Schrijvers
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

8.  STAT1 Gain-of-Function Mutations Cause High Total STAT1 Levels With Normal Dephosphorylation.

Authors:  Ofer Zimmerman; Peter Olbrich; Alexandra F Freeman; Lindsey B Rosen; Gulbu Uzel; Christa S Zerbe; Sergio D Rosenzweig; Hye Sun Kuehn; Kevin L Holmes; David Stephany; Li Ding; Elizabeth P Sampaio; Amy P Hsu; Steven M Holland
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

9.  The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC.

Authors:  Kaikai Shen; Yuqing Wei; Tangfeng Lv; Yong Song; Xiaogan Jiang; Zhiwei Lu; Ping Zhan; Xianghai Wang; Meng Fan; Weihua Lu
Journal:  BMC Bioinformatics       Date:  2021-09-29       Impact factor: 3.169

Review 10.  Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity.

Authors:  Georgios Sogkas; Faranaz Atschekzei; Ignatius Ryan Adriawan; Natalia Dubrowinskaja; Torsten Witte; Reinhold Ernst Schmidt
Journal:  Cell Mol Immunol       Date:  2021-04-01       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.